Changes in Weight and Glucose Can Protect Against Progression in Early Diabetes Independent of Improvements in β-Cell Function

Context: Evidence-based strategies to prevent progression of dysglycemia in newly diagnosed type 2 diabetes are needed. Objective: To undertake a secondary analysis of the Early Diabetes Intervention Program (EDIP) in order to understand the features that were protective against worsening glycemia....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The journal of clinical endocrinology and metabolism 2016-11, Vol.101 (11), p.4076-4084
Hauptverfasser: Patel, Y. R, Kirkman, M. S, Considine, R. V, Hannon, T. S, Mather, K. J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4084
container_issue 11
container_start_page 4076
container_title The journal of clinical endocrinology and metabolism
container_volume 101
creator Patel, Y. R
Kirkman, M. S
Considine, R. V
Hannon, T. S
Mather, K. J
description Context: Evidence-based strategies to prevent progression of dysglycemia in newly diagnosed type 2 diabetes are needed. Objective: To undertake a secondary analysis of the Early Diabetes Intervention Program (EDIP) in order to understand the features that were protective against worsening glycemia. Design: EDIP was a randomized, placebo-controlled trial. Setting: Two university diabetes centers. Patients: A total of 219 overweight individuals with fasting glucose < 7.8 mmol/L and 2-hour oral glucose tolerance test (OGTT) glucose > 11.1 mmol/L. Interventions: Acarbose versus placebo, on a background of dietary recommendations, with quarterly visits to assess glycemia and intervention adherence for up to 5 years. Main Outcome Measures: Progression of fasting glucose ≥ 7.8 mmol/L on two consecutive quarterly visits. Cox proportional hazards modeling and ANOVA were performed to evaluate determinants of progression. Results: Progression-free status was associated with reductions in weight, fasting glucose, 2-hour OGTT glucose, and increases in the high-density lipoprotein/triglyceride ratio. The reduction in fasting glucose was the only effect that remained significantly associated with progression-free status in multivariable Cox modeling. The reduction in fasting glucose was in turn primarily associated with reductions in weight and in 2-hour OGTT glucose. Acarbose treatment did not explain these changes. Conclusions: In early diabetes, reductions in glucose, driven by reductions in weight, can delay progressive metabolic worsening. These observations underscore the importance of lifestyle management including weight loss as a tool to mitigate worsening of glycemia in newly diagnosed diabetes. Reductions in fasting glucose, via reductions in weight, provided protection from progressive dysglycemia in EDIP. Lifestyle change can contribute importantly to glycemic control in early diabetes.
doi_str_mv 10.1210/jc.2016-2056
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5095260</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1835428262</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4734-93c4b86f037af2bc88e00355ae4f7258256b5c4b426748d576bb8cf2e18774163</originalsourceid><addsrcrecordid>eNptkctu1TAQhiMEoofCjjXykgUpvsbJBqkKbTlSJViAYGc5PpPLIbGD7bTqinfqg_SZcDilAglL9mjkb_4Z-8-ylwSfEErw2705oZgUOcWieJRtSMVFLkklH2cbjCnJK0m_HWXPQthjTDgX7Gl2RKVgjGG5yX7WvbYdBDRY9BWGro9I2x26GBfjAqBaW_TJuwgmotNODzbENe88hDA4u1adaT_eoPeDbiAmna3dwQzpsBG5Fm2n2bsrmFL6u8fdbV7DOKLzxZqYFJ5nT1o9BnhxH4-zL-dnn-sP-eXHi219epkbLhnPK2Z4UxYtZlK3tDFlCRgzITTwVlJRUlE0IiGcFpKXOyGLpilNS4GUUnJSsOPs3UF3XpoJdibN4_WoZj9M2t8opwf1740detW5KyVwJWiBk8DrewHvfiwQopqGYNJTtAW3BEVKJjgtaUET-uaAGu9C8NA-tCFYrZ6pvVGrZ2r1LOGv_h7tAf5jUgL4Abh2YwQfvo_LNXjVgx5jr3BavJBlvioSkrI8bcpTGTuUJTec8YOFebVN7d3ibfrr_0_zCzaJtJY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835428262</pqid></control><display><type>article</type><title>Changes in Weight and Glucose Can Protect Against Progression in Early Diabetes Independent of Improvements in β-Cell Function</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Patel, Y. R ; Kirkman, M. S ; Considine, R. V ; Hannon, T. S ; Mather, K. J</creator><creatorcontrib>Patel, Y. R ; Kirkman, M. S ; Considine, R. V ; Hannon, T. S ; Mather, K. J</creatorcontrib><description>Context: Evidence-based strategies to prevent progression of dysglycemia in newly diagnosed type 2 diabetes are needed. Objective: To undertake a secondary analysis of the Early Diabetes Intervention Program (EDIP) in order to understand the features that were protective against worsening glycemia. Design: EDIP was a randomized, placebo-controlled trial. Setting: Two university diabetes centers. Patients: A total of 219 overweight individuals with fasting glucose &lt; 7.8 mmol/L and 2-hour oral glucose tolerance test (OGTT) glucose &gt; 11.1 mmol/L. Interventions: Acarbose versus placebo, on a background of dietary recommendations, with quarterly visits to assess glycemia and intervention adherence for up to 5 years. Main Outcome Measures: Progression of fasting glucose ≥ 7.8 mmol/L on two consecutive quarterly visits. Cox proportional hazards modeling and ANOVA were performed to evaluate determinants of progression. Results: Progression-free status was associated with reductions in weight, fasting glucose, 2-hour OGTT glucose, and increases in the high-density lipoprotein/triglyceride ratio. The reduction in fasting glucose was the only effect that remained significantly associated with progression-free status in multivariable Cox modeling. The reduction in fasting glucose was in turn primarily associated with reductions in weight and in 2-hour OGTT glucose. Acarbose treatment did not explain these changes. Conclusions: In early diabetes, reductions in glucose, driven by reductions in weight, can delay progressive metabolic worsening. These observations underscore the importance of lifestyle management including weight loss as a tool to mitigate worsening of glycemia in newly diagnosed diabetes. Reductions in fasting glucose, via reductions in weight, provided protection from progressive dysglycemia in EDIP. Lifestyle change can contribute importantly to glycemic control in early diabetes.</description><identifier>ISSN: 0021-972X</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/jc.2016-2056</identifier><identifier>PMID: 27533307</identifier><language>eng</language><publisher>United States: Endocrine Society</publisher><subject>Acarbose - administration &amp; dosage ; Acarbose - pharmacology ; Adult ; Aged ; Blood Glucose - metabolism ; Combined Modality Therapy ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - therapy ; Diet, Carbohydrate-Restricted - methods ; Diet, Reducing - methods ; Disease Progression ; Female ; Glycoside Hydrolase Inhibitors - administration &amp; dosage ; Glycoside Hydrolase Inhibitors - pharmacology ; Humans ; Insulin-Secreting Cells - metabolism ; Male ; Middle Aged ; Original ; Outcome Assessment (Health Care) ; Overweight - blood ; Overweight - therapy ; Weight Loss</subject><ispartof>The journal of clinical endocrinology and metabolism, 2016-11, Vol.101 (11), p.4076-4084</ispartof><rights>Copyright © 2016 by the Endocrine Society</rights><rights>Copyright © 2016 by The Endocrine Society</rights><rights>Copyright © 2016 by the Endocrine Society 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4734-93c4b86f037af2bc88e00355ae4f7258256b5c4b426748d576bb8cf2e18774163</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27533307$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Patel, Y. R</creatorcontrib><creatorcontrib>Kirkman, M. S</creatorcontrib><creatorcontrib>Considine, R. V</creatorcontrib><creatorcontrib>Hannon, T. S</creatorcontrib><creatorcontrib>Mather, K. J</creatorcontrib><title>Changes in Weight and Glucose Can Protect Against Progression in Early Diabetes Independent of Improvements in β-Cell Function</title><title>The journal of clinical endocrinology and metabolism</title><addtitle>J Clin Endocrinol Metab</addtitle><description>Context: Evidence-based strategies to prevent progression of dysglycemia in newly diagnosed type 2 diabetes are needed. Objective: To undertake a secondary analysis of the Early Diabetes Intervention Program (EDIP) in order to understand the features that were protective against worsening glycemia. Design: EDIP was a randomized, placebo-controlled trial. Setting: Two university diabetes centers. Patients: A total of 219 overweight individuals with fasting glucose &lt; 7.8 mmol/L and 2-hour oral glucose tolerance test (OGTT) glucose &gt; 11.1 mmol/L. Interventions: Acarbose versus placebo, on a background of dietary recommendations, with quarterly visits to assess glycemia and intervention adherence for up to 5 years. Main Outcome Measures: Progression of fasting glucose ≥ 7.8 mmol/L on two consecutive quarterly visits. Cox proportional hazards modeling and ANOVA were performed to evaluate determinants of progression. Results: Progression-free status was associated with reductions in weight, fasting glucose, 2-hour OGTT glucose, and increases in the high-density lipoprotein/triglyceride ratio. The reduction in fasting glucose was the only effect that remained significantly associated with progression-free status in multivariable Cox modeling. The reduction in fasting glucose was in turn primarily associated with reductions in weight and in 2-hour OGTT glucose. Acarbose treatment did not explain these changes. Conclusions: In early diabetes, reductions in glucose, driven by reductions in weight, can delay progressive metabolic worsening. These observations underscore the importance of lifestyle management including weight loss as a tool to mitigate worsening of glycemia in newly diagnosed diabetes. Reductions in fasting glucose, via reductions in weight, provided protection from progressive dysglycemia in EDIP. Lifestyle change can contribute importantly to glycemic control in early diabetes.</description><subject>Acarbose - administration &amp; dosage</subject><subject>Acarbose - pharmacology</subject><subject>Adult</subject><subject>Aged</subject><subject>Blood Glucose - metabolism</subject><subject>Combined Modality Therapy</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - therapy</subject><subject>Diet, Carbohydrate-Restricted - methods</subject><subject>Diet, Reducing - methods</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Glycoside Hydrolase Inhibitors - administration &amp; dosage</subject><subject>Glycoside Hydrolase Inhibitors - pharmacology</subject><subject>Humans</subject><subject>Insulin-Secreting Cells - metabolism</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Original</subject><subject>Outcome Assessment (Health Care)</subject><subject>Overweight - blood</subject><subject>Overweight - therapy</subject><subject>Weight Loss</subject><issn>0021-972X</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkctu1TAQhiMEoofCjjXykgUpvsbJBqkKbTlSJViAYGc5PpPLIbGD7bTqinfqg_SZcDilAglL9mjkb_4Z-8-ylwSfEErw2705oZgUOcWieJRtSMVFLkklH2cbjCnJK0m_HWXPQthjTDgX7Gl2RKVgjGG5yX7WvbYdBDRY9BWGro9I2x26GBfjAqBaW_TJuwgmotNODzbENe88hDA4u1adaT_eoPeDbiAmna3dwQzpsBG5Fm2n2bsrmFL6u8fdbV7DOKLzxZqYFJ5nT1o9BnhxH4-zL-dnn-sP-eXHi219epkbLhnPK2Z4UxYtZlK3tDFlCRgzITTwVlJRUlE0IiGcFpKXOyGLpilNS4GUUnJSsOPs3UF3XpoJdibN4_WoZj9M2t8opwf1740detW5KyVwJWiBk8DrewHvfiwQopqGYNJTtAW3BEVKJjgtaUET-uaAGu9C8NA-tCFYrZ6pvVGrZ2r1LOGv_h7tAf5jUgL4Abh2YwQfvo_LNXjVgx5jr3BavJBlvioSkrI8bcpTGTuUJTec8YOFebVN7d3ibfrr_0_zCzaJtJY</recordid><startdate>201611</startdate><enddate>201611</enddate><creator>Patel, Y. R</creator><creator>Kirkman, M. S</creator><creator>Considine, R. V</creator><creator>Hannon, T. S</creator><creator>Mather, K. J</creator><general>Endocrine Society</general><general>Copyright by The Endocrine Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201611</creationdate><title>Changes in Weight and Glucose Can Protect Against Progression in Early Diabetes Independent of Improvements in β-Cell Function</title><author>Patel, Y. R ; Kirkman, M. S ; Considine, R. V ; Hannon, T. S ; Mather, K. J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4734-93c4b86f037af2bc88e00355ae4f7258256b5c4b426748d576bb8cf2e18774163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Acarbose - administration &amp; dosage</topic><topic>Acarbose - pharmacology</topic><topic>Adult</topic><topic>Aged</topic><topic>Blood Glucose - metabolism</topic><topic>Combined Modality Therapy</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - therapy</topic><topic>Diet, Carbohydrate-Restricted - methods</topic><topic>Diet, Reducing - methods</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Glycoside Hydrolase Inhibitors - administration &amp; dosage</topic><topic>Glycoside Hydrolase Inhibitors - pharmacology</topic><topic>Humans</topic><topic>Insulin-Secreting Cells - metabolism</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Original</topic><topic>Outcome Assessment (Health Care)</topic><topic>Overweight - blood</topic><topic>Overweight - therapy</topic><topic>Weight Loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Patel, Y. R</creatorcontrib><creatorcontrib>Kirkman, M. S</creatorcontrib><creatorcontrib>Considine, R. V</creatorcontrib><creatorcontrib>Hannon, T. S</creatorcontrib><creatorcontrib>Mather, K. J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Patel, Y. R</au><au>Kirkman, M. S</au><au>Considine, R. V</au><au>Hannon, T. S</au><au>Mather, K. J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changes in Weight and Glucose Can Protect Against Progression in Early Diabetes Independent of Improvements in β-Cell Function</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><addtitle>J Clin Endocrinol Metab</addtitle><date>2016-11</date><risdate>2016</risdate><volume>101</volume><issue>11</issue><spage>4076</spage><epage>4084</epage><pages>4076-4084</pages><issn>0021-972X</issn><eissn>1945-7197</eissn><abstract>Context: Evidence-based strategies to prevent progression of dysglycemia in newly diagnosed type 2 diabetes are needed. Objective: To undertake a secondary analysis of the Early Diabetes Intervention Program (EDIP) in order to understand the features that were protective against worsening glycemia. Design: EDIP was a randomized, placebo-controlled trial. Setting: Two university diabetes centers. Patients: A total of 219 overweight individuals with fasting glucose &lt; 7.8 mmol/L and 2-hour oral glucose tolerance test (OGTT) glucose &gt; 11.1 mmol/L. Interventions: Acarbose versus placebo, on a background of dietary recommendations, with quarterly visits to assess glycemia and intervention adherence for up to 5 years. Main Outcome Measures: Progression of fasting glucose ≥ 7.8 mmol/L on two consecutive quarterly visits. Cox proportional hazards modeling and ANOVA were performed to evaluate determinants of progression. Results: Progression-free status was associated with reductions in weight, fasting glucose, 2-hour OGTT glucose, and increases in the high-density lipoprotein/triglyceride ratio. The reduction in fasting glucose was the only effect that remained significantly associated with progression-free status in multivariable Cox modeling. The reduction in fasting glucose was in turn primarily associated with reductions in weight and in 2-hour OGTT glucose. Acarbose treatment did not explain these changes. Conclusions: In early diabetes, reductions in glucose, driven by reductions in weight, can delay progressive metabolic worsening. These observations underscore the importance of lifestyle management including weight loss as a tool to mitigate worsening of glycemia in newly diagnosed diabetes. Reductions in fasting glucose, via reductions in weight, provided protection from progressive dysglycemia in EDIP. Lifestyle change can contribute importantly to glycemic control in early diabetes.</abstract><cop>United States</cop><pub>Endocrine Society</pub><pmid>27533307</pmid><doi>10.1210/jc.2016-2056</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-972X
ispartof The journal of clinical endocrinology and metabolism, 2016-11, Vol.101 (11), p.4076-4084
issn 0021-972X
1945-7197
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5095260
source MEDLINE; Journals@Ovid Complete; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Acarbose - administration & dosage
Acarbose - pharmacology
Adult
Aged
Blood Glucose - metabolism
Combined Modality Therapy
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - therapy
Diet, Carbohydrate-Restricted - methods
Diet, Reducing - methods
Disease Progression
Female
Glycoside Hydrolase Inhibitors - administration & dosage
Glycoside Hydrolase Inhibitors - pharmacology
Humans
Insulin-Secreting Cells - metabolism
Male
Middle Aged
Original
Outcome Assessment (Health Care)
Overweight - blood
Overweight - therapy
Weight Loss
title Changes in Weight and Glucose Can Protect Against Progression in Early Diabetes Independent of Improvements in β-Cell Function
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T09%3A33%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changes%20in%20Weight%20and%20Glucose%20Can%20Protect%20Against%20Progression%20in%20Early%20Diabetes%20Independent%20of%20Improvements%20in%20%CE%B2-Cell%20Function&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=Patel,%20Y.%20R&rft.date=2016-11&rft.volume=101&rft.issue=11&rft.spage=4076&rft.epage=4084&rft.pages=4076-4084&rft.issn=0021-972X&rft.eissn=1945-7197&rft_id=info:doi/10.1210/jc.2016-2056&rft_dat=%3Cproquest_pubme%3E1835428262%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1835428262&rft_id=info:pmid/27533307&rfr_iscdi=true